MASAI
2023
Mammography Screening with Artificial Intelligence trial
In 105,934 women in population-based mammography screening, AI-supported screen reading was non-inferior to standard double reading without AI for interval cancer rate, with higher cancer detection and a 44.2% lower screen-reading workload.
Result
Efficacy: Interval cancer rate (20% non-inferiority margin)ratio 0.88 (95% CI 0.65-1.18)
Below 1 favours AI-supported screen reading, above 1 favours standard double reading without AI.
Event rates AI-supported screen reading 1.55 vs standard double reading without AI 1.76 per 1,000
Also reported: Sensitivity 80.5% vs 73.8% (P=0.031), specificity 98.5% in both. Cancer detection 6.4 vs 5.0 per 1,000 (ratio 1.29, 95% CI 1.09–1.51; P=0.0021); screen-reading workload −44.2%. Interim safety analysis in 80,033 women: detection 6.1 vs 5.1 per 1,000 (ratio 1.2, 95% CI 1.0–1.5), workload −44.3%.
- Subtopic
- AI-supported double reading
- Design
- Population-based single-blinded non-inferiority RCT, Sweden
- Relevance
- Practice-defining: a trial the field needs to know.
- Source
- Lång K, et al. Lancet Oncol. 2023;24(8):936-944; Hernström V, et al. Lancet Digit Health. 2025;7(3):e175-e183; Gommers J, et al. Lancet. 2026;407(10527):505-514.doi 10.1016/S1470-2045(23)00298-X
Discussion & critique
The first randomised trial of AI in mammography screening and the anchor of the cluster: AI triage nearly halved radiologist reading with no loss of safety, more (mostly small, node-negative) cancers detected, and a non-inferior interval cancer rate at two years. One AI system (Transpara) at four sites of one Swedish programme with double reading as comparator, so the result does not transfer directly to single-reader programmes; whether earlier detection lowers breast cancer mortality is beyond the trial. PRAIM and ScreenTrustCAD are the non-randomised companions.